CN106309631A - Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin - Google Patents
Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin Download PDFInfo
- Publication number
- CN106309631A CN106309631A CN201610839069.2A CN201610839069A CN106309631A CN 106309631 A CN106309631 A CN 106309631A CN 201610839069 A CN201610839069 A CN 201610839069A CN 106309631 A CN106309631 A CN 106309631A
- Authority
- CN
- China
- Prior art keywords
- radix glycyrrhizae
- fructus rosae
- rosae laevigatae
- norfloxacin
- drug resistance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 title claims abstract description 20
- 229960001180 norfloxacin Drugs 0.000 title claims abstract description 20
- 244000144977 poultry Species 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 title abstract description 9
- 244000144972 livestock Species 0.000 title abstract description 5
- 241000825107 Hierochloe Species 0.000 claims 1
- 235000015466 Hierochloe odorata Nutrition 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 description 37
- 241000193830 Bacillus <bacterium> Species 0.000 description 29
- 210000001072 colon Anatomy 0.000 description 29
- 241000287828 Gallus gallus Species 0.000 description 23
- 235000013330 chicken meat Nutrition 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 17
- 235000013594 poultry meat Nutrition 0.000 description 10
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 8
- 229960003022 amoxicillin Drugs 0.000 description 8
- 235000021050 feed intake Nutrition 0.000 description 8
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 8
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 7
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 description 7
- 108010078777 Colistin Proteins 0.000 description 7
- 229960004467 ceftiofur sodium Drugs 0.000 description 7
- 229960003346 colistin Drugs 0.000 description 7
- 229960003760 florfenicol Drugs 0.000 description 7
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 7
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 7
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 7
- 229960004821 amikacin Drugs 0.000 description 6
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 6
- IZJAOWYNDLDRKM-UHFFFAOYSA-N sodium;(4-aminophenyl)sulfonyl-(6-methoxypyrimidin-4-yl)azanide Chemical compound [Na+].C1=NC(OC)=CC([N-]S(=O)(=O)C=2C=CC(N)=CC=2)=N1 IZJAOWYNDLDRKM-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 239000008155 medical solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- -1 LIJUNJING Chemical compound 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- PZUUTJLAUKMLTH-UHFFFAOYSA-N [F].C1=CC=CC=C1 Chemical compound [F].C1=CC=CC=C1 PZUUTJLAUKMLTH-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004273 floxacillin Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- WOZOCNSIPFNZFR-UHFFFAOYSA-N pyrimidine;sodium Chemical compound [Na].C1=CN=CN=C1 WOZOCNSIPFNZFR-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin, made from norfloxacin, Radix Glycyrrhizae and Fructus Rosae Laevigatae at a weight ratio of 1:(20-25):(2-5). The invention also claims a compound preparation prepared with the above livestock and poultry compound drug. The livestock and poultry compound drug has the advantage that experimental studies prove that the joint use of the norfloxacin, Radix Glycyrrhizae and Fructus Rosae Laevigatae at a weight ratio provides significant synergy, high acting speed, low cost and other features.
Description
Technical field
The invention belongs to poultry compound medicine technical field, particularly relate to a kind of containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin
Poultry compound medicine, infected, by colon bacillus, the disease that causes for treating poultry.
Background technology
After poultry are infected by colon bacillus, the multiple locations such as acute sepsis, peritonitis, hepatitis, pneumonia, enteritis can be caused
Severe infections, causes huge economic loss to livestock and poultry cultivation.Amoxicillin, florfenicol etc. are to prevent and treat commonly using of this type of disease
Western medicine, along with medication is more and more spread unchecked, its Resistant strain is the most, and drug cost is the most increasing, but therapeutic effect and
Drug resistance situation is not taken a turn for the better, and goes from bad to worse on the contrary.
Through retrieval, do not inquire and Radix Glycyrrhizae, Fructus Rosae Laevigatae and Western medicine are combined for treating poultry by colon bacillus sense
The relevant report of the disease that dye causes.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicines containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin
Thing, its synergism is obvious, it is possible to eliminate the colon bacillus drug resistance to norfloxacin, improves therapeutic effect.
For solving above technical problem, the present invention by the following technical solutions: a kind of containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin
Poultry compound medicine, be made up of norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae, the weight ratio of norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is
1:20-25:2-5。
The present invention is also claimed by the compound preparation become prepared by above-mentioned poultry compound medicine.
The present invention possesses and provides the benefit that: prove through experimental study, and norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae are with specific weight
Amount ratio is used in combination, and has synergism obvious, and curative effect is fast, low cost and other advantages.
Detailed description of the invention
Below in conjunction with specific embodiment, technical scheme and beneficial effect are described further, except Special Statement
Outward, Radix Glycyrrhizae of the present invention, Fructus Rosae Laevigatae weight are dry weight.
One, Radix Glycyrrhizae, the Fructus Rosae Laevigatae mensuration to the drug resistance elimination effect of Western medicine
1. assay method
According to the weight ratio of Western medicine and Radix Glycyrrhizae, Fructus Rosae Laevigatae be 1:10:1,1:20:2,1:20:5,1:30:5,1:25:4,1:
40:5 prepares Western medicine and Radix Glycyrrhizae, the admixing medical solutions of Fructus Rosae Laevigatae respectively；Choose the bacterial strain to Western medicine drug resistance as subjects, utilization
Plate dilution method carries out Secondary Culture, measures each process medicinal liquid MIC situation of change to Resistant strain；Set Radix Glycyrrhizae, Fructus Rosae Laevigatae simultaneously
Western medicine single dose sub, each is sun comparison, compares as the moon if being not added with any medicine.
Above-mentioned process was cultivated for 3 generations the most continuously.
2. result of the test
After cultivating for 3 generations continuously, the process flat board of cloudy comparison is long bacterium, and other each medicaments and admixing medical solutions are for large intestine angstrom
The result statistics of the MIC (μ g/mL) of uncommon Salmonella is as shown in table 1:
Can be concluded that by upper table
1. when the weight ratio of amoxicillin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:20:2,1:20:5, amoxicillin pair
The minimal inhibitory concentration of drug resistance colon bacillus all reduces more than 16 times, it is seen then that drug resistance colon bacillus is to amoxicillin
Drug resistance substantially reduce.And when the weight ratio of amoxicillin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:25:4,1:30:5 and 1:40:5,
Amoxicillin to the minimal inhibitory concentration of drug resistance colon bacillus be not added with Radix Glycyrrhizae, the sun of Fructus Rosae Laevigatae compares (pure Western medicine) phase
Ratio, does not has significant change.
2. when the weight ratio of florfenicol and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:20:2,1:20:5, florfenicol pair
The minimal inhibitory concentration of drug resistance colon bacillus all reduces more than 8 times, it is seen then that drug resistance colon bacillus is to florfenicol
Drug resistance substantially reduces.And when the weight ratio of florfenicol and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:25:4,1:30:5 and 1:40:5, fluorine
Benzene Buddhist nun examine the minimal inhibitory concentration to drug resistance colon bacillus be not added with Radix Glycyrrhizae, Fructus Rosae Laevigatae sun comparison (pure Western medicine) compared with,
There is no significant change.
3. when the weight ratio of colistin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:2,1:20:5,1:25:4, colistin pair
The minimal inhibitory concentration of drug resistance colon bacillus all reduces more than 16 times, it is seen then that drug resistance colon bacillus is to colistin
Drug resistance substantially reduce.And when the weight ratio of colistin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:30:5 and 1:40:5,
Colistin to the minimal inhibitory concentration of drug resistance colon bacillus be not added with Radix Glycyrrhizae, the sun of Fructus Rosae Laevigatae compares (pure Western medicine) phase
Ratio, does not has significant change.
4. when the weight ratio of amikacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:2,1:20:5,1:25:4, amikacin pair
The minimal inhibitory concentration of drug resistance colon bacillus all reduces more than 4 times, it is seen then that drug resistance colon bacillus is to amikacin
Drug resistance substantially reduces.And when the weight ratio of amikacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:30:5 and 1:40:5, Ah
Meter Ka Xing to the minimal inhibitory concentration of drug resistance colon bacillus compared with sun comparison (pure Western medicine) being not added with Radix Glycyrrhizae, Fructus Rosae Laevigatae,
There is no significant change.
5. when the weight ratio of sulfamonomethoxine sodium and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:5,1:25:4, methoxy between sulfanilamide
More than pyrimidine sodium all subtracts 16 to the minimal inhibitory concentration of drug resistance colon bacillus times, it is seen then that drug resistance colon bacillus is to sulphur
Between amine, the drug resistance of Sulfamonomethoxine sodium substantially reduces.And when the weight ratio of sulfamonomethoxine sodium and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:
When 10:1,1:20:2,1:30:5 and 1:40:5, the sulfamonomethoxine sodium minimal inhibitory concentration to drug resistance colon bacillus
Compared with sun comparison (pure Western medicine) being not added with Radix Glycyrrhizae, Fructus Rosae Laevigatae, there is no significant change.
6., when the weight ratio of LIJUNJING and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:5, LIJUNJING is to drug resistance colon bacillus
Minimal inhibitory concentration all reduces more than 64 times, it is seen then that the drug resistance of LIJUNJING is substantially reduced by drug resistance colon bacillus.And work as
The weight ratio of LIJUNJING and Radix Glycyrrhizae, Fructus Rosae Laevigatae is and when 1:10:1,1:20:2,1:25:4,1:30:5,1:40:5, LIJUNJING pair
The minimal inhibitory concentration of drug resistance colon bacillus is compared with sun comparison (pure Western medicine) being not added with Radix Glycyrrhizae, Fructus Rosae Laevigatae, the most substantially
Change.
7. when the weight ratio of norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:2,1:20:5,1:25:4, norfloxacin pair
The minimal inhibitory concentration of drug resistance colon bacillus all reduces more than 4 times, it is seen then that drug resistance colon bacillus is to norfloxacin
Drug resistance substantially reduces.And when the weight ratio of norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:30:5 and 1:40:5, promise
Flucloxacillin to the minimal inhibitory concentration of drug resistance colon bacillus compared with sun comparison (pure Western medicine) being not added with Radix Glycyrrhizae, Fructus Rosae Laevigatae,
There is no significant change.
8., when the weight ratio of ceftiofur sodium and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20:5,1:25:4, ceftiofur sodium is to drug resistance
The minimal inhibitory concentration of colon bacillus all reduces more than 16 times, it is seen then that drug resistance colon bacillus is to ceftiofur sodium
Drug resistance substantially reduces.And when the weight ratio of ceftiofur sodium and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:10:1,1:20:2,1:30:5 and 1:
During 40:5, ceftiofur sodium to the minimal inhibitory concentration of drug resistance colon bacillus be not added with Radix Glycyrrhizae, the sun of Fructus Rosae Laevigatae compares (pure
Western medicine) compare, there is no significant change.
9. when the combination weight ratio of fosfomycin and Radix Glycyrrhizae, Fructus Rosae Laevigatae be 1:10:1,1:20:2,1:20:5,1:25:4,1:
When 30:5,1:40:5, to the minimal inhibitory concentration of drug resistance colon bacillus be not added with Radix Glycyrrhizae, the sun of Fructus Rosae Laevigatae compares (pure west
Medicine) compare, there is no significant change.
Two, the experiment in vitro that Western medicine and Radix Glycyrrhizae, Fructus Rosae Laevigatae are used in combination
By amoxicillin, florfenicol, colistin, amikacin, sulfamonomethoxine sodium, LIJUNJING, promise fluorine sand
Star, 8 kinds of Western medicine of ceftiofur sodium are that 1:20:5 mixes with Radix Glycyrrhizae (powder) and Fructus Rosae Laevigatae (powder) according to weight ratio respectively, make scattered
Agent, respectively as test group 1#-8#；Separately set amoxicillin, florfenicol, colistin, amikacin, sulfamonomethoxine
Sodium, LIJUNJING, norfloxacin, ceftiofur sodium, Radix Glycyrrhizae single dose, Fructus Rosae Laevigatae single dose, Radix Glycyrrhizae+Fructus Rosae Laevigatae (20:5) are respectively as right
According to group 1#-11#.
Subjects is the chicken group making a definite diagnosis and having infected E.coli from chickens disease.
Morbidity chicken group is divided into 19 groups of administrations.The equal SM of each group 5 days.
Dosage and result of the test are as shown in the table:
| Group | Dosage (g) | Situation after sick chicken medication 5 days |
| Test group 1# | 4 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 2# | 4 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 3# | 8 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 4# | 6 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 5# | 4 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 6# | 4 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 7# | 4 | Feed intake increased, and without dead, chicken group be almost recovered |
| Test group 8# | 10 | Feed intake increased, and without dead, chicken group be almost recovered |
| Matched group 1# | 0.2 | Great majority still wan, has the sick chicken death of 3% |
| Matched group 2# | 0.2 | Great majority still wan, has the sick chicken death of 7% |
| Matched group 3# | 0.4 | Great majority still wan, has the sick chicken death of 2% |
| Matched group 4# | 0.3 | Great majority still wan, has the sick chicken death of 5% |
| Matched group 5# | 0.2 | Great majority still wan, has the sick chicken death of 5% |
| Matched group 6# | 0.2 | Great majority still wan, has the sick chicken death of 4% |
| Matched group 7# | 0.2 | Great majority still wan, has the sick chicken death of 9% |
| Matched group 8# | 0.5 | Great majority still wan, has the sick chicken death of 3% |
| Matched group 9# | 10 | Great majority still wan, has the sick chicken death of 15% |
| Matched group 10# | 10 | Great majority still wan, has the sick chicken death of 14% |
| Matched group 11# | 10 | Great majority still wan, has the sick chicken death of 17% |
Claims (2)
1. one kind containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and the poultry compound medicine of norfloxacin, it is characterised in that by norfloxacin and sweet
Grass, Fructus Rosae Laevigatae composition, the weight ratio of norfloxacin and Radix Glycyrrhizae, Fructus Rosae Laevigatae is 1:20-25:2-5.
2. by the compound preparation become prepared by the poultry compound medicine described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610839069.2A CN106309631A (en) | 2016-09-21 | 2016-09-21 | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610839069.2A CN106309631A (en) | 2016-09-21 | 2016-09-21 | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309631A true CN106309631A (en) | 2017-01-11 |
Family
ID=57819570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610839069.2A Withdrawn CN106309631A (en) | 2016-09-21 | 2016-09-21 | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309631A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989730A (en) * | 2014-05-28 | 2014-08-20 | 广西大学 | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry |
-
2016
- 2016-09-21 CN CN201610839069.2A patent/CN106309631A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103989730A (en) * | 2014-05-28 | 2014-08-20 | 广西大学 | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106139121A (en) | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and colistin | |
| CN106309631A (en) | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin | |
| CN106237311A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and colistin | |
| CN106266058A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and amikacin | |
| CN106266057A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and amoxicillin | |
| CN106236883A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and sulfamonomethoxine sodium | |
| CN106236884A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and ceftiofur sodium | |
| CN106138321A (en) | A kind of poultry compound medicine containing Radix Glycyrrhizae, Fructus Rosae Laevigatae and LIJUNJING | |
| CN106309633A (en) | Livestock and poultry compound drug with Cortex Cinnamomi, Fructus Rosae Laevigatae and florfenicol | |
| CN106309632A (en) | Livestock and poultry compound drug with Cortex Cinnamomi, Fructus Rosae Laevigatae and norfloxacin | |
| CN106266056A (en) | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and amoxicillin | |
| CN106266055A (en) | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and sulfamonomethoxine sodium | |
| CN106266060A (en) | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and amikacin | |
| CN106334011A (en) | Liquorice, fructus rosae laevigatae and florfenicol-containing compound medicine for livestock | |
| CN106109638A (en) | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and LIJUNJING | |
| CN106138320A (en) | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and norfloxacin | |
| CN106309634A (en) | Composite medicine containing cinnamon, cherokee rose fruit and ceftiofur sodium for beasts and birds | |
| CN106266054A (en) | A kind of poultry compound medicine containing Cortex Cinnamomi, Fructus Rosae Laevigatae and LIJUNJING | |
| CN106138318A (en) | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and amoxicillin | |
| CN106266051A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and amikacin | |
| CN106266052A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and fosfomycin | |
| CN106109639A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and LIJUNJING | |
| CN106266053A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and amoxicillin | |
| CN106236882A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and florfenicol | |
| CN106267154A (en) | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and colistin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170111 |